Clinical trial · Observational
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
Use of Novel Biomarkers and Echocardiography to Assess Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 months post completion of anthracycline chemotherapy. They will participate in blood and imaging tests with a goal of determining the best method for predicting the occurrence of cardiotoxicity in this subpopulation.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anthracycline Induced Cardiomyopathy | — | UNRESOLVED | — |
| Biomarkers | — | UNRESOLVED | — |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cardiotoxicity | — | UNRESOLVED | — |
| Echocardiography | — | UNRESOLVED | — |
| Heart Failure | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Association of Heart Failure Biomarkers with Global Longitudinal strain rate
- timeFrame
- up to 35 weeks
- description
- N Terminal-proBNP, hs troponin, ST2, galectin-3 with global longitudinal strain rate
Secondary outcomes (8)
- measure
- Prediction of initiation/change in cardiovascular medications based on serum biomarkers
- timeFrame
- up to 35 weeks
- description
- NT-proBNP
- measure
- Prediction of initiation/change in cardiovascular medications based on serum biomarkers
- timeFrame
- up to 35 weeks
- description
- ST2
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female subjects aged 18-85 years old 2. Biopsy-proven diagnosis of invasive breast cancer carcinoma 3. Plan for anthracycline inclusive chemotherapy (+/- taxanes, +/- trastuzumab) Exclusion Criteria: 1. History of major heart disease at the time of breast cancer diagnosis (myocardial infarction or known left ventricular dysfunction (LVD) at baseline (defined as ejection fraction \<40%) 2. History of known obstructive coronary artery disease (CAD), or coronary revascularization within the past 1 year 3. History of clinical heart failure or previous heart failure hospitalization 4. Patients with elevations in NT-pro BNP (above 3x ULN), or ST2 (above 2x ULN), galectin-3 (above 2x ULN), or hs troponin (above 2x ULN) during baseline screening 5. Patients with metastatic disease or recurrent breast cancer at diagnosis 6. History of other chemotherapy treated malignancy
References
Publications (0)
Data not yet available